Drug Profile
Research programme: prostate cancer therapeutics - Colby Pharmaceuticals
Alternative Names: CPC-410Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Colby Pharmaceuticals
- Class Small molecules
- Mechanism of Action Antioxidants; Oncogene protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Prostate cancer
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Prostate-cancer in USA
- 01 Oct 2012 Preclinical development is ongoing in the US
- 07 Feb 2011 Research programme: prostate cancer therapeutics - Colby is available for licensing as of 27 Feb 2007. http://www.colbypharma.com